Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis by Gayle, A et al.
ORIGINAL RESEARCH
Healthcare Resource Utilization Among Patients
in England with Systemic Sclerosis-Associated
Interstitial Lung Disease: A Retrospective Database
Analysis
Alicia Gayle . Nils Schoof . Margarida Alves . Deborah Clarke .
Christina Raabe . Prithwiraj Das . Francesco Del Galdo .
Toby M. Maher
Received: February 7, 2020
 The Author(s) 2020
ABSTRACT
Introduction: Systemic sclerosis-associated inter-
stitial lung disease (SSc-ILD) places a substantial
burden on patients and healthcare systems. The
objectives of this study were to describe clinical
characteristics and assess healthcare resource
utilization and costs of patients with SSc-ILD in
England, compared with patients with non-
pulmonary organ involvement related to SSc
(SSc-OOI).
Methods: This population-based retrospective
study used data from the Clinical Practice
Research Datalink linked to Hospital Episode
Statistics. Data were extracted from medical
records dated January 1, 2005 to March 31,
2016. Patients with SSc were identified and
placed in subgroups based on organ involve-
ment: SSc-ILD, SSc-OOI, and both (SSc-ILD-
OOI). Patients with SSc-ILD-OOI were included
in both the SSc-ILD and SSc-OOI subgroups. All-
cause healthcare costs, excluding medication
costs, were calculated to 2016 British pounds
sterling (£).
Results: This study included 675 patients with
SSc: 174 (26%) had neither ILD nor other organ
involvement (OOI); 127 (19%) had SSc-ILD; 477
(71%) had SSc-OOI; 103 (15%) had SSc-ILD-
OOI. Age-weighted median [interquartile range
(IQR)] annual healthcare costs per patient were:
£1496 (£664–£2817) in SSc only; £6375 (£3451–
£15,041) in SSc-ILD; £4084 (£1454–£10,105) in
SSc-OOI; £6632 (£4023–£17,009) in SSc-ILD-
OOI. In multivariate analysis, older age at
diagnosis, diagnosis of anemia, and number of
comorbid diseases were associated with higher
yearly healthcare costs.
Conclusion: The annual healthcare cost for
patients with SSc-ILD is substantial, and higher
than that of patients with SSc-OOI or SSc only.
These results quantify the economic burden of
SSc-ILD in a real-world setting, and highlight
the need for treatment of this disease.
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PLAIN LANGUAGE SUMMARY
SSc is a rare disease that causes fibrosis, or thick-
ening, of the skin. In some patients, SSc can also
affect the lungs (‘SSc-ILD’) or other organs, e.g.,
the heart (‘SSc-OOI’). Patients with SSc-ILD typi-
callyhavehighhealthcare costs; however, it isnot
clear how costs for SSc-ILD compare with those
for SSc-OOI. To investigate this, we evaluated the
costs associatedwith SSc-ILD and compared them
with those for SSc only or SSc-OOI. In this Eng-
land-based study, the annual healthcare costs for
patients with SSc-ILD were approximately 50%
higher than for those without lung disease (SSc
only) or SSc-OOI. These results highlight the
importance of promptly diagnosing and treating
patients with lung fibrosis complicating SSc.
Keywords: CPRD; Electronic health records;
Healthcare utilization; Interstitial lung disease;
Observational study; SSc-ILD; Systemic sclerosis
Key Summary Points
Systemic sclerosis (SSc) is a rare
autoimmune disease involving the skin
and internal organs, ultimately leading to
fibrosis and organ dysfunction.
As part of the systemic involvement, the
disease affects the lungs (SSc-ILD), other
organs (SSc-OOI), or both the lungs and
other organs (SSc-ILD-OOI).
SSc-ILD is a substantial burden on patients
and healthcare services. The aim of this
real-world observational study was to
evaluate the clinical characteristics and
healthcare resource utilization of patients
with SSc, SSc-ILD, and SSc-OOI in
England.
Patients with SSc-ILD have high annual
healthcare costs that exceed those of
patients with SSc or SSc-OOI.
These data show that SSc-ILD represents a
high economic burden, and highlight the
need for timely diagnosis and treatment
to minimize healthcare costs.
INTRODUCTION
Systemic sclerosis (SSc) is a rare, heterogeneous,
chronic autoimmune disease that is character-
ized by fibrosis of the skin and is associated with
high mortality [1, 2]. The prevalence of SSc is
estimated to be 7.2–33.9 and 13.5–44.3 per
100,000 individuals in Europe and North
America, respectively [3, 4]. Patients can
develop organ involvement associated with SSc,
including pulmonary hypertension, interstitial
lung disease (ILD), gastrointestinal disorders,
and cardiac and renal involvement [2].
Systemic sclerosis-associated interstitial lung
disease (SSc-ILD), in which patients experience
parenchymal infiltration leading to lung fibrosis
and worsening respiratory symptoms, is a lead-
ing cause of SSc-related deaths [5, 6]. It is esti-
mated that 30–52% of patients with SSc develop
SSc-ILD [3]. Nintedanib is the first treatment
approved by the U.S. Food & Drug Administra-
tion that slows the rate of decline in pulmonary
function in patients with SSc-ILD [7, 8]. In
addition, the Committee for Medicinal Products
for Human Use of the European Medicines
Agency adopted a positive opinion for ninte-
danib as a therapy for adult patients with SSc-
ILD [9]. Several immunosuppressants are used
in SSc-ILD based on varying levels of evidence
[10], and a 2020 Delphi consensus recommends
treatment with cyclophosphamide, mycophe-
nolate mofetil, or nintedanib [11]. Whilst
immunosuppression is important in SSc man-
agement, there is also a need to address lung
fibrosis in SSc-ILD, as it is a major cause of
mortality.
Available data suggest that SSc is associated
with a substantial clinical and economic bur-
den. A 2017 review identified six studies
reporting on SSc-associated costs to patients
and/or healthcare systems in five countries
(Canada, France, Italy, Spain, USA) [12].
Although limited data are available regarding
the healthcare resource utilization (HCRU) of
patients with SSc-ILD, recent work in the USA
suggests that care of these patients is associated
with greater healthcare-related costs than the
care of patients with SSc who do not have lung
involvement [13, 14]. No data are available
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regarding the economic burden of SSc or SSc-
ILD in England.
The aims of this population-based cohort
study were: to describe the clinical characteris-
tics of patients diagnosed with SSc, SSc-ILD, and
SSc with other organ involvement (SSc-OOI); to
estimate HCRU and costs among patients with
SSc, SSc-ILD, and SSc-OOI; and to identify pre-
dictors for total costs among patients with SSc-
ILD.
METHODS
Study Design
This retrospective database analysis used both
primary care records from the Clinical Practice
Research Datalink (CPRD) GOLD database, and
secondary care records relating to the admitted
patient care, accident and emergency (A&E),
and outpatient care from the Hospital Episode
Statistics (HES) database between Jan-
uary 1, 2005 and March 31, 2016 (defined as the
study period).
Generic ethical approval for observational
research using the CPRD with approval from
Independent Scientific Advisory Committee
(ISAC) was granted by a Health Research
Authority (HRA) Research Ethics Committee
(REC) (East Midlands—Derby, REC reference
number 05/MRE04/87). The protocol for this
research was approved by the ISAC for the
Medicines and Healthcare products Regulatory
Agency (MHRA) Database Research (protocol
number 16_262R2). Informed consent was not
needed because of the anonymity of the CPRD
data. This study was performed in adherence to
the Declaration of Helsinki.
Patient Population
Patients were included in this study if they
were: (1) listed in the CPRD database and their
record could be linked with HES; (2) registered
with a practice of acceptable standard as defined
in the CPRD; (3) first diagnosed with SSc within
the study period, with at least 12 months of
available data in CPRD/HES before and after
diagnosis; and (4) at least 18 years old at time of
diagnosis. The date of first diagnosis was the
index date for the follow-up period, which las-
ted for the remainder of the study period.
Patients entering the database after March 31,
2015 or participating in a clinical trial during
the study period were excluded. Due to the
requirement for HES linkage, the population
was limited to patients from England.
Patients with SSc, with or without ILD and
OOI, were identified using the National Health
Service’s (NHS) Read Code [15, 16] and the
International Classification of Diseases (10th
edition) [17] for primary care and secondary
care records, respectively, in combination with
modified European League Against Rheumatism
(EULAR) classification criteria (Table S1 and
Table S2) [18]. Included EULAR criteria were:
skin thickening of the fingers, fingertip pitting
scars, Raynaud’s phenomenon, pulmonary
arterial hypertension (PAH), and/or ILD. The
date of the last recorded EULAR symptom code
was included as the diagnosis and index date.
Two distinct subgroup analyses were per-
formed: the clinical subgroup analysis and the
diagnosis subgroup analysis. The clinical sub-
group analysis aimed to assess the costs associ-
ated with SSc-ILD and to compare these with
the costs associated with SSc-OOI. Data from all
patients were used in both subgroup analyses.
For the clinical subgroup analysis, subgroups
were defined based on the presence and nature
of organ complications: SSc-ILD, SSc-OOI, and
SSc-ILD and SSc-OOI (SSc-ILD-OOI). Patients
were considered to have OOI if they had one or
more of: angina, atrial fibrillation (AF), coro-
nary heart disease (CHD), difficulty swallowing,
diarrhea, dry mouth, heartburn, motor distur-
bances and dyspepsia, pericardial effusions, or
renal crisis. The SSc-ILD and SSc-OOI subgroups
were not mutually exclusive; patients with SSc-
ILD-OOI were included in both the SSc-ILD and
SSc-OOI subgroups, as well as the SSc-ILD-OOI
subgroup. For the diagnosis subgroup analysis,
three subgroups were defined based on the
healthcare setting in which patients received
their diagnosis: primary setting, secondary set-
ting, and both settings. The primary and sec-
ondary setting subgroups were not mutually
exclusive; patients who received diagnoses in
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both primary and secondary care were included
in the primary and secondary setting subgroups,
as well as the both settings subgroup.
Outcomes
The primary outcomes of this study were the
descriptive statistics for demographics, patient
and clinical characteristics, including comor-
bidities (according to the Charlson Comorbidity
index), medical history, and pharmacotherapies
prescribed in primary care 90 days before and
12 months after diagnosis, by subgroup.
As secondary outcomes, HCRU statistics were
captured under the following categories: inpa-
tient stays, A&E visits, general practitioner (GP)
visits, prescriptions issued, and outpatient vis-
its. For each of these, the number and percent-
age of patients with at least one outcome, the
number of unique instances of each outcome,
overall costs, and per patient costs were col-
lected. The average length of inpatient stay was
recorded, and attendances were grouped by
Healthcare Resource Group (HRG) codes. Pre-
dictors for total costs by clinical subgroup were
calculated. Therapies were identified from pri-
mary care prescription records/codes and
grouped by drug class. Data regarding pharma-
cotherapies were only analyzed in the CPRD.
Cost estimates were derived from NHS reference
costs [19] and are given in 2016 British pounds
sterling (£).
Statistical Methodology
Predictors of total cost in the overall population
were derived using a multivariate generalized
linear model with a gamma distribution and
log-link function to allow for non-normal costs.
Backward selection was used to identify a par-
simonious model for the association between
our identified covariates and total healthcare
costs. Backward variable selection was per-
formed using an a = 0.05 criterion. Inclusion of
‘‘age’’ and ‘‘gender’’ was forced, as these variables
were a priori considered important. A set of
variables, corresponding to the variables
remaining in the model at the end of the
selection procedure, was then created.
Statistical comparisons between subgroups
in the clinical and diagnostic analyses were not
conducted due to overlap between subgroups (a
patient with SSc-ILD and OOI would be counted
in the SSc-ILD, SSc-OOI, and SSc-ILD-OOI
groups; similarly, a patient with a diagnosis in
primary and secondary settings would be
counted in the primary, secondary, and both
settings subgroups). No p values are presented
and comparisons are made using absolute
numbers with no invocation of statistical
significance.
RESULTS
Patient Demographics and Characteristics
In total, 675 patients met the inclusion criteria
(Fig. 1). Demographics, patient and clinical
characteristics—including comorbidities—over-
all and by clinical and diagnosis subgroups, are
presented in Table 1. The mean [standard devi-
ation (SD)] age was 62 (17) years; 79% of the
population were women. Most patients were
white (85%) and lived in the south of England
(65%), and half (50%) were overweight (body
mass index[25 kg/m2).
Comorbidities and manifestations of SSc
were frequent in the overall population
(Table 1). Raynaud’s phenomenon was recorded
in 58% of patients. Gastroesophageal reflux
disease (GERD) was recorded in 48% of patients,
and anemia was recorded in 28%. Most patients
(60%) were hospitalized at least once in the year
before diagnosis. Only 16% of patients had a
computed tomography (CT) scan at diagnosis.
Clinical Subgroup Analysis
Within the overall patient population, 127
patients (19%) were included in the SSc-ILD
subgroup and 477 (71%) in the SSc-OOI sub-
group (Table 1). The SSc-ILD-OOI subgroup
contained 103 patients (15%). Patients with
both ILD and OOI comprised 81% of the SSc-
ILD subgroup and 22% of the SSc-OOI sub-
group. Of 675 patients with SSc, 174 (26%) had
neither ILD nor OOI.
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GERD was reported more frequently in
patients with SSc-ILD or SSc-OOI than in the
overall population of patients with SSc. PAH
was more common in patients with SSc-ILD
than in patients with SSc or SSc-OOI. A higher
proportion of the SSc-ILD subgroup presented
with Raynaud’s phenomenon compared with
the overall SSc population and the SSc-OOI
subgroup (Table 1).
Diagnosis Subgroup Analysis
Of all patients (N = 675) diagnosed with SSc,
485 (72%) had their diagnosis recorded in
primary care, 264 (39%) had their diagnosis
recorded in secondary care, and 74 (11%) had
their diagnosis recorded in both (Table 1). A
smaller proportion of patients in the primary
setting subgroup were hospitalized in the year
prior to diagnosis (n = 213, 44%), compared
with the secondary (n = 257, 97%) and both
settings (n = 68, 92%) subgroups.
In the primary and secondary setting sub-
groups, the most commonly reported comor-
bidities were Raynaud’s phenomenon, GERD,
and anemia. In the both settings subgroup,
Raynaud’s phenomenon, GERD, and PAH were
the most commonly reported comorbidities.
Fig. 1 Cohort selection flowchart. CPRD Clinical Practice Research Datalink, EULAR European League Against
Rheumatism, GP general practitioner, HES Hospital Episode Statistics, SSc systemic sclerosis
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Table 1 Demographics and clinical characteristics of patients diagnosed with SSc; SSc-ILD, SSc-OOI, SSc-ILD-OOI; in
primary care, secondary care, or both
SSc
(n = 675)
Clinical subgroup analysis Diagnostic subgroup analysis
SSc-ILD
(n = 127)
SSc-OOI
(n = 477)
SSc-ILD and
SSc-OOI
(n = 103)
Primary care
diagnosis
(n = 485)
Secondary
care diagnosis
(n = 264)
Diagnosis in
both care
settings
(n = 74)
Female 531 (79) 95 (75) 379 (79) 76 (74) 385 (79) 202 (77) 56 (76)
Age at diagnosis,
years
(mean ± SD)
62 ± 17 71 ± 13 65 ± 18 74 ± 13 62 ± 17 62 ± 17 62 ± 17
Race
White 572 (85) 104 (82) 419 (88) 86 (83) 405 (84) 236 (89) 69 (93)
Black 18 (3) 5 (4) 14 (3) 5 (5) 12 (2) 8 (3) \ 5 (3)
Asian 26 (4) 9 (7) 18 (4) 8 (8) 16 (3) 11 (4) \ 5 (1)
Other 13 (2) 6 (5) 9 (2) \ 5 (2) 7 (1) 7 (3) \ 5 (1)
Missing 46 (7) \ 5 (2) 17 (4) \ 5 (2) 45 (9) \ 5 (1) \ 5 (1)
BMI
Underweight
(\ 18.5 kg/
m2)
34 (5) 8 (6) 24 (5) 6 (6) 24 (5) 14 (5) \ 5 (5)
Normal
(18.5–24.9 kg/
m2)
275 (41) 43 (34) 200 (42) 38 (37) 208 (43) 100 (38) 33 (45)
Overweight
(C 25 kg/m2)
339 (50) 72 (57) 234 (49) 55 (53) 239 (49) 133 (50) 33 (45)
Missing 27 (4) \ 5 (3) 19 (4) \ 5 (4) 14 (3) 17 (6) \ 5 (5)
Smoking history
Non-smoker 243 (36) 39 (31) 165 (35) 32 (31) 193 (40) 71 (27) 21 (28)
Current 97 (14) 12 (9) 68 (14) 8 (8) 74 (15) 39 (15) 16 (22)
Ex-smoker 144 (21) 31 (24) 106 (22) 28 (27) 103 (21) 54 (20) 13 (18)
Missing 191 (28) 45 (35) 138 (29) 35 (34) 115 (24) 100 (38) 24 (32)
Region (UK)
North 131 (19) 22 (17) 99 (21) 16 (16) 98 (20) 50 (19) 17 (23)
South 436 (65) 84 (66) 301 (63) 69 (67) 309 (64) 171 (65) 44 (59)
East or West 108 (16) 21 (17) 77 (16) 18 (17) 78 (16) 43 (16) 13 (18)
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Table 1 continued
SSc
(n = 675)
Clinical subgroup analysis Diagnostic subgroup analysis
SSc-ILD
(n = 127)
SSc-OOI
(n = 477)
SSc-ILD and
SSc-OOI
(n = 103)
Primary care
diagnosis
(n = 485)
Secondary
care diagnosis
(n = 264)
Diagnosis in
both care
settings
(n = 74)
Comorbidities
Calcinosis 15 (2) \ 5 (2) 11 (2) \ 5 (1) 11 (2) \ 5 (2) 0 (0)
Raynaud’s
phenomenon
389 (58) 88 (69) 285 (60) 71 (69) 303 (62) 155 (59) 69 (93)
Esophageal
dysmotility
93 (14) 20 (16) 91 (19) 20 (19) 65 (13) 37 (14) 9 (12)
Sclerodactyly 14 (2) \ 5 (2) 10 (2) \ 5 (3) 10 (2) 5 (2) \ 5 (1)
Telangiectasia 26 (4) \ 5 (2) 15 (3) \ 5 (2) 20 (4) 12 (5) 6 (8)
PAH 109 (16) 52 (41) 94 (20) 43 (42) 72 (15) 68 (26) 31 (42)
GERD 324 (48) 72 (57) 284 (60) 67 (65) 230 (47) 129 (49) 35 (47)
Anemia 191 (28) 49 (39) 159 (33) 42 (41) 123 (25) 90 (34) 22 (30)
Low
hemoglobin
143 (21) 40 (32) 118 (25) 34 (33) 90 (19) 76 (29) 23 (31)
MCV 25 (4) 7 (6) 17 (4) \ 5 (3) 16 (3) 15 (6) 6 (8)
Acute RF 6 (1) \ 5 (3) 5 (1) \ 5 (4) \ 5 (1) \ 5 (1) \ 5 (1)
Dysrhythmia 128 (19) 43 (34) 114 (24) 38 (37) 81 (17) 71 (27) 24 (32)
Organ
transplant
7 (1) \ 5 (2) 5 (1) \ 5 (1) 6 (1) 5 (2) \ 5 (5)
Right heart
catheterization
\ 5 (0) \ 5 (2) \ 5 (0) \ 5 (2) 0 (0) \ 5 (1) 0 (0)
CT scan 105 (16) 37 (29) 86 (18) 33 (32) 79 (16) 47 (18) 21 (28)
Hospitalizations in the year before diagnosis
0 273 (40) 34 (27) 159 (33) 27 (26) 272 (56) 7 (3) 6 (8)
1–19 338 (50) 73 (57) 265 (56) 59 (57) 190 (39) 199 (75) 51 (69)
C 20 64 (9) 20 (16) 53 (11) 17 (17) 23 (5) 58 (22) 17 (23)
Data are shown in numbers (%), unless otherwise indicated
BMI body mass index, CT computed tomography, GERD gastroesophageal reflux disease, MCV mean corpuscular volume,
PAH pulmonary arterial hypertension, RF respiratory failure, SD standard deviation, SSc systemic sclerosis, SSc-ILD
systemic sclerosis-associated interstitial lung disease, SSc-OOI systemic sclerosis with other organ involvement, UK United
Kingdom
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Pharmacotherapies Prescribed in Primary
Care
Similar proportions of patients in each sub-
group were prescribed pharmacotherapies (by
treatment type), in both the clinical and diag-
nosis subgroup analyses (Table 2). In the
90 days prior to diagnosis, 345 patients (51%)
did not receive pharmacotherapy in primary
care. Glucocorticoids and calcium channel
blockers were the most commonly prescribed
pharmacotherapies, both before and after SSc
diagnosis. In the 12 months after recorded
diagnosis, 41% of patients were prescribed glu-
cocorticoids. All types of glucocorticoids were
prescribed more frequently after diagnosis,
compared with before (Supplementary
Table S3). In contrast, the recorded use of
mycophenolate mofetil following SSc diagnosis
was low (fewer than 5 patients in total).
Healthcare Resource Utilization
The rate of healthcare resource usage (GP visits,
outpatient and inpatient stays, A&E atten-
dances) among patients with SSc-ILD, OOI, or
both was consistently higher than in patients
with only SSc (Table 3). Patients with SSc-ILD
and SSc-ILD-OOI had the highest rates of inpa-
tient stays (2.7 and 2.8, respectively), outpatient
visits (9.5 and 9.7), A&E attendances (0.8 and
0.8), and GP visits (16.2 and 16.9) per person-
year.
Patients with a recorded diagnosis in sec-
ondary care, or secondary and primary care had
higher HCRU rates than patients with a diag-
nosis in primary care.
Healthcare Costs
Age-weighted median [interquartile range
(IQR)] healthcare costs per patient-year in the
clinical subgroup analysis were higher for
patients with SSc-ILD [£6375 (£3451–£15,041)]
or SSc-ILD and OOI [£6632 (£4023–£17,009)]
than for patients with SSc-OOI [£4084
(£1454–£10,105)] or SSc only [£1496
(£664–£2817)] (Fig. 2a). Results were similar for
crude data.T
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Each patient with SSc-ILD had, on average,
10 outpatient visits per year, at a total yearly
median cost of £813. In comparison, patients
with SSc-OOI averaged seven outpatient visits at
a total yearly median cost of £608
(Tables S4 and S5).
Results of sensitivity analyses showed that
healthcare costs were consistently the highest
for patients with SSc-ILD (with or without OOI),
after excluding patients with cardiovascular
disease (CVD; defined as angina, AF, and CHD)
(Fig. 2b), as well as among patients who died
during follow-up (Fig. 2c) and those with ane-
mia (Fig. 2d). Overall, median age-weighted
healthcare costs were higher in patients with
CVD [£5507 (£1660–£14,886)], anemia [£5915
(£2368–£14,259)], and in those who died
[£9751 (£4550–£26,645)] compared with
patients who did not have CVD [£2874
(£1060–£7316)], anemia [£2321 (£888–£6447)],
or did not die [£2068 (£936–£5201)] (Fig. 2).
An investigation into potential predictors of
total healthcare costs in the overall population,
using a multivariate generalized linear model,
showed a significant association between costs
and older age at diagnosis, a diagnosis of ane-
mia, and the total number of comorbidities
based on incremental increases in the Charslon
Comorbidity index (all p\ 0.0001).
Inpatient Stays and Costs
Inpatient stays were the main contributor to
healthcare costs in the entire cohort of patients
with SSc [median (IQR)], £1627 (£109–6023);
Table S5] and across all clinical subgroups
except for the SSc-only subgroup, in which
outpatient stays were the major cost
Fig. 2 Median all-cause healthcare costs per patient-year
(a); after excluding patients with CVD (b); among patients
who died during follow-up (c); and among patients with
anemia (d). All-cause healthcare costs are shown in British
pounds sterling (£) and do not include medication. All
data in b–d are age-weighted. CVD was defined as AF,
angina, or CHD. AF atrial fibrillation, CHD coronary
heart disease, CVD cardiovascular disease, SSc systemic
sclerosis, SSc-ILD systemic sclerosis-associated interstitial
lung disease, SSc-OOI systemic sclerosis with other organ
involvement
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contributor. This was true for patients with
CVD and SSc, and patients with SSc only. In
patients with age-weighted annual costs of
C £15,000 (n = 77), inpatient stays were still the
main contributor to overall cost, including in
patients (n = 6) with SSc only (Table S5E). Of all
790 inpatient attendances, 414 (52%) were day
admissions, 287 (36%) were non-elective
admissions, and 89 (11%) were ordinary elective
admissions (pre-planned with a duration of
more than 1 day). The proportions of the dif-
ferent admission types were consistent across all
clinical subgroups (data not shown).
The median length of inpatient stay was less
than 1 day, indicating that most patients who
were hospitalized left the same day (Table 4).
This was consistent across diagnostic and clini-
cal subgroups. The median duration of elective
stays was 5 days (IQR 3–7), as was the median
duration of non-elective stays (IQR 3–11). These
findings were also consistent across all clinical
subgroups (data not shown). Based on grouping
of attendances according to HRG subchap-
ter codes, the main drivers of inpatient costs
appeared to be related to connective tissue dis-
orders (23%), the respiratory system (13%),
cardiac surgery and primary cardiac conditions
(13%), the digestive system (10%), and the
vascular system (7%).
DISCUSSION
The clinical and economic burden of SSc is
substantial [13]. Although it is thought that ILD
contributes significantly to the cost of SSc, there
is limited evidence regarding the patient char-
acteristics and HCRU associated with SSc-ILD
outside of the USA. Through analysis of patient
care records from the CPRD and HES databases,
this study identified 675 patients with SSc in
England. Of these, 19% had ILD and 71% had
OOI. The median (IQR) age-weighted annual
healthcare cost of a patient with SSc-ILD was
estimated to be £6375 (£3451–£15,041), which
is larger than that of a patient with SSc-OOI
[£4084 (£1454–£10,105)] or SSc alone [£1496
(£664–£2817)]. To date, no other comparisons
between HCRU in patients with SSc-ILD and
patients with SSc and OOI have been reported,
nor have data regarding the HCRU of patients
with SSc-ILD in England.
Our finding that SSc-ILD is associated with
greater costs than SSc alone is supported by
three published studies using US-based data
[13, 14, 20]. A study published in 2012 used a
national healthcare claims database to assess
the burden of SSc from 2003–2008. In addition
to finding that patients with SSc had higher
healthcare-related costs than matched controls,
the authors noted that the cost for patients with
SSc-ILD over 1 year was 2.3-times that of
patients with SSc alone [20]. An analysis of data
from two administrative claims databases also
found that patients with SSc-ILD had greater
costs than patients with SSc alone during the
study period (2003–2014). The largest costs
among patients with SSc-ILD and patients with
SSc-PAH were for outpatient pharmacy claims
[20]. The final study used claims data from
2005–2015 to compare healthcare costs
between patients with SSc-ILD and matched
controls [14]. Patients with SSc-ILD had higher
costs than those without, and results were
compared with a study of patients with SSc with
otherwise similar methodology. In this com-
parison, SSc-ILD was associated with higher cost
than SSc [14, 21]. Our study differs from these
US claims-based studies [13, 14, 20] in that
patient inclusion was based on primary and
secondary care records generated as part of
standard healthcare, and is therefore more
likely to reflect the general population. This is
in contrast to claims-based studies, which
extract data from insured individuals only and
therefore may not be representative of the
whole population [13, 14, 20].
Two studies have reported analyses of pre-
dictors of increased cost in patients with SSc
[20, 22]. One study, conducted in Canada,
found that, while older age was associated with
increasing direct cost, younger age was associ-
ated with higher overall cost. This study inclu-
ded indirect costs, and the association between
younger age and increased cost reflects the
greater lost productivity associated with
removal of a younger person from the labor
market [22]. The other study, conducted in the
USA, found that ages 45–64 years were associ-
ated with increased cost compared to ages
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18–44 years. The authors also found that ILD,
gastrointestinal bleeding, and renal disease were
associated with higher cost [20], which is con-
sistent with our finding that a higher number of
comorbidities is associated with higher cost.
The associations between comorbidities and
high cost suggest that prevention and early
treatment (where cost-effective) of these disor-
ders could help reduce costs for patients with
SSc, including those with SSc-ILD.
Most patients with SSc (61%) in our study
had a first recorded diagnosis in primary care.
The most frequent clinical manifestations
(GERD, Raynaud’s phenomenon, PAH, anemia)
were similar across care settings and disease
subgroups, which is consistent with observa-
tions of early multiorgan involvement [23].
Although no approved pharmacotherapies
for SSc-ILD were available during the study
period, an analysis of the European Scleroderma
Trials and Research patient database suggested
that SSc-ILD is frequently managed by off-label
use of immunosuppressants, such as
cyclophosphamide, mycophenolate mofetil,
and glucocorticoids [10]. The European Sclero-
derma Observational Study found that treat-
ment with cyclophosphamide was associated
with significantly greater rates of change in
forced vital capacity over time than mycophe-
nolate mofetil, methotrexate, or no immuno-
suppression in patients with early diffuse
cutaneous SSc and pulmonary fibrosis [24]. An
analysis of a USA claims database using data
from 2009–2014 found that 52% of patients
Table 4 Length of inpatient stays by patients diagnosed: with SSc; SSc-ILD, SSc-OOI, or SSc-ILD and SSc-OOI (A); in
primary care, secondary care, or both (B)
SSc
(n = 675)
A. Clinical subgroup analysis B. Diagnostic subgroup analysis
SSc only
(n = 174)
SSc-ILD
(n = 127)
SSc-OOI
(n = 477)
SSc-ILD
and SSc-
OOI
(n = 103)
Primary
care
diagnosis
(n = 485)
Secondary
care
diagnosis
(n = 264)
Diagnosis
in both
settings
(n = 74)
Inpatient stays
Total
admissions, n
3701 522 1037 3023 881 2306 1692 297
Length of stay
in days, median
(IQR)
0 (0–2) 0 (0–1) 0 (0–3) 0 (0–2) 0 (0–3) 0 (0–1) 0 (0–2) 0 (0–3)
Inpatient day
admissions
(0 days
duration),
n (%)
2460 (66) 347 (66) 667 (64) 2002 (66) 556 (63) 1562 (68) 1048 (62) 150 (51)
Inpatient stays,
1–2 days
duration, n (%)
426 (12) 58 (11) 104 (10) 346 (11) 82 (9) 265 (11) 233 (14) 72 (24)
Inpatient
stays, C 3 days
duration, n (%)
815 (22) 117 (22) 266 (26) 675 (22) 243 (28) 479 (21) 411 (24) 75 (25)
IQR interquartile range, SSc systemic sclerosis, SSc-ILD systemic sclerosis-associated interstitial lung disease, SSc-OOI
systemic sclerosis with other organ involvement
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with SSc-ILD received glucocorticoids, 19%
received mycophenolate mofetil, and 9%
received cyclophosphamide [13]. In our study,
the use of mycophenolate mofetil was extre-
mely limited in the overall population and in
the SSc-ILD subgroup (both\5%), and use of
cyclophosphamide was not observed. Pharma-
cotherapy use was derived solely from CPRD
records, which include only primary care data.
Hence, the infrequent prescribing of recom-
mended immunosuppressants suggests that SSc-
ILD is managed outside of a primary care set-
ting. It is also worth noting that mycophenolate
mofetil was not included in the 2017 EULAR
treatment guidelines, as the first randomized
clinical trial of mycophenolate mofetil in SSc-
ILD was published in 2016, which was too late
for inclusion in the guidelines [25, 26].
In our study, patients with a diagnosis in
secondary care had higher HCRU rates com-
pared with patients diagnosed in primary care
or both. Most inpatient stays did not result in
patients being admitted overnight. Although
pharmacotherapy was only directly captured in
primary care, these inpatient stays could reflect
administration of treatment (such as
cyclophosphamide) in secondary care. There-
fore, these inpatient stays potentially represent
a cost that could be reduced if patients were to
be treated with a therapy that does not require
administration in a hospital or tertiary care
setting. However, these stays could also capture
consultant visits, admissions for procedures,
administration of other drugs, or disease-related
events leading to hospitalization.
Guidelines published by EULAR in 2009 and
2017 do not recommend glucocorticoids in the
treatment of SSc or SSc-ILD, and only note that
they are associated with an increased risk of
scleroderma renal crisis [25, 27]. In the current
study, 27% of all patients received glucocorti-
coids 9 months prior to diagnosis, compared
with 41% 12 months after. Of patients with SSc-
ILD, 41% received glucocorticoids before diag-
nosis, compared with 64% after. While gluco-
corticoids are not recommended for the
treatment of SSc-ILD, they are used to treat
idiopathic inflammatory myopathies, which
can overlap with SSc [1, 28–30]. The treatment
of patients with SSc and SSc-ILD in this study
could, therefore, represent treatment of patients
with musculoskeletal involvement, as well as
off-label, unrecommended use of
glucocorticoids.
This study had multiple strengths, including
the large, real-world dataset of patients with SSc
that was used. Data were gathered over a long
follow-up period. It is likely that a large pro-
portion of the patient population included in
this study comprised patients with clear diag-
noses of SSc. Despite this, this study is limited in
that these diagnoses were not externally vali-
dated. There are likely to have been further
patients who were not identified from the
dataset due to inadequate coding. Another
potential limitation is that CPRD data extrac-
tion is dependent on general practices agreeing
to participate, and contains data for only 6.9%
of the United Kingdom population [31]. How-
ever, patients in the CPRD are thought to be
broadly representative of the general popula-
tion [31]. Total healthcare costs were estimated
from NHS reference lists and did not include
medication costs. Costs arising from prescrip-
tions and tests in secondary care (such as
genetic tests or high-resolution CT scans) were
not captured.
CONCLUSIONS
This observational study characterized the SSc
patient population in England for the first time,
and found that HCRU costs were higher for
patients with SSc-ILD than for patients with SSc
but without ILD, irrespective of OOI. The
descriptive characteristics and cost estimates
reported here may support the development of
strategies to facilitate earlier diagnosis and
management of SSc and SSc-ILD. These results
may also be included as inputs in future eco-
nomic models to evaluate the cost-effectiveness
of SSc-ILD treatment options.
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